​

Coherus BioSciences (CHRS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CHRS Stock Forecast

Coherus BioSciences (CHRS) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 435.71% increase from the last price of $1.12.

- $1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $1.12

CHRS Stock Rating

Coherus BioSciences stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (75.00%), 4 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 4 12 Strong Sell Sell Hold Buy Strong Buy

CHRS Price Target Upside V Benchmarks

TypeNameUpside
StockCoherus BioSciences435.71%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$1.12$1.12$1.12
Upside/Downside--435.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25131--5
Mar, 25241--7
Feb, 25241--7
Jan, 25241--7
Dec, 24242--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024Colleen KusyRobert W. Baird$6.00$1.74244.83%435.71%
Nov 14, 2022J.P. Morgan$11.00$7.7941.21%882.14%
Jun 13, 2022Ashwani VermaUBS$7.00$6.1913.09%525.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 16, 2024UBSBuyNeutraldowngrade
May 30, 2024Cowen & Co.BuyBuyhold
May 10, 2024H.C. WainwrightBuyBuyhold
Mar 28, 2023UBSNeutralBuyupgrade
Jun 13, 2022UBSNeutralinitialise
Apr 26, 2022Zacks Investment ResearchHoldupgrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.85$-4.06$-4.21$-2.53$0.25----
Avg Forecast$1.72$-3.62$-3.62$-1.94$0.35$-0.43$-0.73$-0.75$-0.64
High Forecast$2.21$-2.97$-2.46$-1.07$0.36$-0.24$0.09$-0.42$-0.35
Low Forecast$1.41$-4.65$-4.36$-2.44$0.35$-0.54$-1.44$-0.95$-0.80
Surprise %7.56%12.15%16.30%30.41%-28.57%----

Revenue Forecast

$50M $160M $270M $380M $490M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$475.82M$326.55M$211.04M$257.24M$266.96M----
Avg Forecast$480.32M$335.74M$213.31M$262.80M$256.37M$217.04M$267.61M$240.11M$324.87M
High Forecast$585.63M$409.35M$246.88M$314.63M$306.93M$278.88M$320.39M$287.46M$388.94M
Low Forecast$414.69M$289.86M$160.88M$172.65M$168.42M$91.90M$175.81M$157.74M$213.42M
Surprise %-0.94%-2.74%-1.06%-2.11%4.13%----

Net Income Forecast

$-8B $-6B $-4B $-3B $-1B $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$132.24M$-306.32M$-326.63M$-237.89M$28.51M----
Avg Forecast$124.92M$-6.15B$-197.44M$-237.89M$33.26M$-36.83M$-44.81M$-70.94M$-60.26M
High Forecast$149.91M$-4.92B$-157.95M$-190.31M$33.73M$-22.54M$8.79M$-39.30M$-33.39M
Low Forecast$99.94M$-7.38B$-236.92M$-285.47M$32.78M$-51.12M$-135.49M$-89.12M$-75.71M
Surprise %5.86%-95.02%65.43%--14.28%----

CHRS Forecast FAQ

Is Coherus BioSciences stock a buy?

Coherus BioSciences stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Coherus BioSciences is a favorable investment for most analysts.

What is Coherus BioSciences's price target?

Coherus BioSciences's price target, set by 16 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 435.71% change from the previous closing price of $1.12.

How does Coherus BioSciences stock forecast compare to its benchmarks?

Coherus BioSciences's stock forecast shows a 435.71% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Coherus BioSciences over the past three months?

  • April 2025: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Coherus BioSciences’s EPS forecast?

Coherus BioSciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.43, marking a -272.00% decrease from the reported $0.25 in 2024. Estimates for the following years are $-0.73 in 2026, $-0.75 in 2027, and $-0.64 in 2028.

What is Coherus BioSciences’s revenue forecast?

Coherus BioSciences's average annual revenue forecast for its fiscal year ending in December 2025 is $217.04M, reflecting a -18.70% decrease from the reported $266.96M in 2024. The forecast for 2026 is $267.61M, followed by $240.11M for 2027, and $324.87M for 2028.

What is Coherus BioSciences’s net income forecast?

Coherus BioSciences's net income forecast for the fiscal year ending in December 2025 stands at $-36.831M, representing a -229.20% decrease from the reported $28.51M in 2024. Projections indicate $-44.814M in 2026, $-70.936M in 2027, and $-60.264M in 2028.